← Back to screener

NewAmsterdam Pharma Co N.V. NAMS

Rank #2322 · Nasdaq · $2.3B market cap
Audited by Deloitte Accountants B.V, no going-concern flag in the latest filing.
Score
24.5
P/E
-13.3
P/B
5.45
ROE
-41.1%
Op. Margin
-1298.6%
Debt Ratio
25%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -13.3x, P/B 5.45x. Ranks in the top 75% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -41.1%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 25%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 86.3% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2023$0.1B$-0.0B$-0.0B$-0.1B-34.1-66
2024$0.1B$-0.0B$-0.0B$-0.1B-3.5-52
2025$0.0B$-0.2B$-0.2B$0.4B-1298.625

← See the full screener